Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
9 stopped studies mapped to Adult B Acute Lymphoblastic Leukemia and descendants · 78% state a reason
Over the 9 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Aug 3, 2011 | Albert Einstein College of Medicine | not stated | Not stated |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic… | Phase 2 | terminated | May 2, 2014 | National Cancer Institute (NCI) | Slow accrual. | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 24, 2025source: clinicaltrials